Paper: Real-World Outcomes with Fedratinib Therapy in Patients Who Discontinued Ruxolitinib for Primary Myelofibrosis

Real-world Outcomes of Fedratinib in Patients with Myelofibrosis who Discontinued Ruxolitinib

Read the full article here

Related Articles